Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Breast Cancer

  Free Subscription


1 Am J Surg
1 Ann Oncol
1 Ann Surg Oncol
4 BMC Cancer
1 Br J Cancer
3 Breast Cancer
1 Breast Cancer (Auckl)
4 Breast Cancer (Dove Med Press)
9 Breast Cancer Res
3 Breast Cancer Res Treat
2 Cancer
1 Cancer Cell
2 Cancer Lett
1 Cancer Res
6 Clin Breast Cancer
2 Clin Cancer Res
1 Clin Exp Metastasis
3 Eur J Cancer
1 Eur J Surg Oncol
1 Eur Radiol
1 Gene
1 Histopathology
2 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Clin Invest
3 J Clin Oncol
2 J Natl Cancer Inst
1 Lancet
1 Nat Rev Clin Oncol
2 NPJ Breast Cancer
2 Pathology
3 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Surg

  1. DRAPALIK LM, Shenk R, Rock L, Simpson A, et al
    Should breast surgery be considered for patients with de novo metastatic inflammatory breast cancer?
    Am J Surg. 2024 Mar 2:S0002-9610(24)00068-0. doi: 10.1016/j.amjsurg.2024.
    PubMed         Abstract available

    Ann Oncol

  2. AGOSTINETTO E, Buisseret L, Salgado R, Kok M, et al
    Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: Does it help tailor adjuvant treatment?
    Ann Oncol. 2024 Mar 12:S0923-7534(24)00077-2. doi: 10.1016/j.annonc.2024.

    Ann Surg Oncol

  3. NGUYEN CL, Cui R, Zhou M, Ali F, et al
    Cost-Effectiveness of Radar Localisation Versus Wire Localisation for Wide Local Excision of Non-palpable Breast Cancer.
    Ann Surg Oncol. 2024 Mar 12. doi: 10.1245/s10434-024-15142.
    PubMed         Abstract available

    BMC Cancer

  4. BOULIFA A, Raftery MJ, Franzen AS, Radecke C, et al
    Role of beta-(1-->3)(1-->6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures.
    BMC Cancer. 2024;24:339.
    PubMed         Abstract available

  5. KNUDSEN BM, Sondergaard SR, Stacey D, Steffensen KD, et al
    Impact of timing and format of patient decision aids for breast cancer patients on their involvement in and preparedness for decision making - the IMPACTT randomised controlled trial protocol.
    BMC Cancer. 2024;24:336.
    PubMed         Abstract available

  6. MAENPAA N, Tiainen L, Hamalainen M, Luukkaala T, et al
    Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.
    BMC Cancer. 2024;24:331.
    PubMed         Abstract available

  7. PALMER S, Blomqvist C, Holmqvist M, Lindman H, et al
    Validation of primary and outcome data quality in a Swedish population-based breast cancer quality registry.
    BMC Cancer. 2024;24:329.
    PubMed         Abstract available

    Br J Cancer

  8. TEN VELDE DE, Duijm LEM, van der Sangen MJC, Schipper RJ, et al
    Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme.
    Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02633.
    PubMed         Abstract available

    Breast Cancer

  9. KANG D, Park S, Kim HJ, Lee J, et al
    Comprehensive Young Age Breast Cancer registry from clinical, genomics, and patient-reported outcomes measured with 15 years follow-up: the CHARM cohort profile.
    Breast Cancer. 2024 Mar 12. doi: 10.1007/s12282-024-01559.
    PubMed         Abstract available

  10. LI G, Lin X, Wang X, Cai L, et al
    Enhancing radiosensitivity in triple-negative breast cancer through targeting ELOB.
    Breast Cancer. 2024 Mar 12. doi: 10.1007/s12282-024-01554.
    PubMed         Abstract available

  11. HU X
    The role of the BTLA-HVEM complex in the pathogenesis of breast cancer.
    Breast Cancer. 2024 Mar 14. doi: 10.1007/s12282-024-01557.
    PubMed         Abstract available

    Breast Cancer (Auckl)

  12. AZHARI RAD R, Naghdi Y, Majidi Jamalabadi M, Masoumi S, et al
    Tissue Engineering Scaffolds Loaded With a Variety of Plant Extracts: Novel Model in Breast Cancer Therapy.
    Breast Cancer (Auckl). 2024;18:11782234241236358.
    PubMed         Abstract available

    Breast Cancer (Dove Med Press)

  13. LI Q, Gao C, Zhao X, Li J, et al
    An Analysis of Preoperative Inflammatory Indicators That Influence the Drainage Tube Retention Time in Patients with Breast Cancer Surgery.
    Breast Cancer (Dove Med Press). 2024;16:91-103.
    PubMed         Abstract available

  14. SHARMAN MOSER S, Apter L, Livnat I, Ginsburg R, et al
    Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting.
    Breast Cancer (Dove Med Press). 2024;16:105-116.
    PubMed         Abstract available

  15. MA Q, Liu YB, She T, Liu XL, et al
    The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients.
    Breast Cancer (Dove Med Press). 2024;16:117-126.
    PubMed         Abstract available

  16. ZHOU Y, Xue W, Meng X, Bhandari A, et al
    GNPNAT1 is a Biomarker That Predicts a Poor Prognosis of Breast Cancer.
    Breast Cancer (Dove Med Press). 2024;16:71-89.
    PubMed         Abstract available

    Breast Cancer Res

  17. JIANG X, Wang Y, Guo L, Wang Y, et al
    The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.
    Breast Cancer Res. 2024;26:37.
    PubMed         Abstract available

  18. ZHAO L, Xing Y, Liu C, Ma S, et al
    Detection of HER2 expression using (99m)Tc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial.
    Breast Cancer Res. 2024;26:40.
    PubMed         Abstract available

  19. LI J, Liang Y, Zhou S, Chen J, et al
    UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.
    Breast Cancer Res. 2024;26:44.
    PubMed         Abstract available

  20. BAEZ-NAVARRO X, van den Ende NS, Nguyen AH, Sinke R, et al
    HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
    Breast Cancer Res. 2024;26:41.
    PubMed         Abstract available

  21. CONNER SJ, Guarin JR, Le TT, Fatherree JP, et al
    Cell morphology best predicts tumorigenicity and metastasis in vivo across multiple TNBC cell lines of different metastatic potential.
    Breast Cancer Res. 2024;26:43.
    PubMed         Abstract available

  22. JACOBS LM, Helder LS, Albers KI, Kranendonk J, et al
    The role of surgical tissue injury and intraoperative sympathetic activation in postoperative immunosuppression after breast-conserving surgery versus mastectomy: a prospective observational study.
    Breast Cancer Res. 2024;26:42.
    PubMed         Abstract available

  23. PEREIRA A, Garmendia ML, Leiva V, Corvalan C, et al
    Breast composition during and after puberty: the Chilean Growth and Obesity Cohort Study.
    Breast Cancer Res. 2024;26:45.
    PubMed         Abstract available

  24. SHATSKY RA, Batra-Sharma H, Helsten T, Schwab RB, et al
    Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
    Breast Cancer Res. 2024;26:46.

  25. GONZALEZ-FERNANDEZ L, Romero-Morales C, Martinez-Pascual B, Rio-Gonzalez A, et al
    Breast cancer survivors suffering from lymphedema: What really do affect to corporeality/body image? A qualitative study.
    Breast Cancer Res. 2024;26:47.
    PubMed         Abstract available

    Breast Cancer Res Treat

  26. WU Q, Hatse S, Kenis C, Fernandez-Garcia J, et al
    Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases.
    Breast Cancer Res Treat. 2024 Mar 13. doi: 10.1007/s10549-024-07260.
    PubMed         Abstract available

  27. CHUNG HL, Middleton LP, Sun J, Whitman GJ, et al
    Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants.
    Breast Cancer Res Treat. 2024 Mar 12. doi: 10.1007/s10549-024-07261.
    PubMed         Abstract available

  28. FARLAND LV, Lind KE, Thomson CA, Saquib N, et al
    Infertility and risk of postmenopausal breast cancer in the women's health initiative.
    Breast Cancer Res Treat. 2024 Mar 9. doi: 10.1007/s10549-024-07257.
    PubMed         Abstract available


  29. WU J, Wang W, Gao L, Shao X, et al
    Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
    Cancer. 2024 Mar 14. doi: 10.1002/cncr.35270.
    PubMed         Abstract available

  30. PUKLIN LS, Ferrucci LM, Harrigan M, McGowan C, et al
    Improving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35280.
    PubMed         Abstract available

    Cancer Cell

  31. BEJARANO L, Kauzlaric A, Lamprou E, Lourenco J, et al
    Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms.
    Cancer Cell. 2024;42:378-395.
    PubMed         Abstract available

    Cancer Lett

  32. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
    Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
    Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
    PubMed         Abstract available

  33. BULLOCK KK, Shattuck-Brandt R, Scalise C, Luo W, et al
    Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.
    Cancer Lett. 2024;586:216681.
    PubMed         Abstract available

    Cancer Res

  34. QIU Y, Wang X, Sun Y, Jin T, et al
    ACSL4-mediated membrane phospholipid remodeling induces integrin beta1 activation to facilitate triple-negative breast cancer metastasis.
    Cancer Res. 2024 Mar 12. doi: 10.1158/0008-5472.CAN-23-2491.
    PubMed         Abstract available

    Clin Breast Cancer

  35. JANSSON M, Lindberg J, Rask G, Svensson J, et al
    Stromal Type I Collagen in Breast Cancer: Correlation to Prognostic Biomarkers and Prediction of Chemotherapy Response.
    Clin Breast Cancer. 2024 Feb 21:S1526-8209(24)00053.
    PubMed         Abstract available

  36. NISHIMURA R, Fujiki Y, Taira T, Miyaki T, et al
    The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes.
    Clin Breast Cancer. 2024 Feb 22:S1526-8209(24)00051.
    PubMed         Abstract available

  37. SASA S, Inoue H, Nakagawa M, Toba H, et al
    Long-Term Outcomes of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy (N-1 Study, Phase II Trial) in Patients With Operable Breast Cancer.
    Clin Breast Cancer. 2024 Feb 22:S1526-8209(24)00052.
    PubMed         Abstract available

  38. LORENTZEN EH, Minami CA
    Avoiding Locoregional Overtreatment in Older Adults With Early-Stage Breast Cancer.
    Clin Breast Cancer. 2024 Feb 13:S1526-8209(24)00042.
    PubMed         Abstract available

  39. DOUGLAS E, Levine B, Ansari A, Ansley K, et al
    Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer.
    Clin Breast Cancer. 2024 Feb 16:S1526-8209(24)00044.
    PubMed         Abstract available

  40. PANG J, Yan Z, Tan QT, Allen JC, et al
    Feasibility of Omitting Sentinel Lymph Node Biopsy in an Under-screened Cohort of Breast Cancer Patients With a Premastectomy Diagnosis of Ductal Carcinoma In Situ.
    Clin Breast Cancer. 2024 Feb 5:S1526-8209(24)00040.
    PubMed         Abstract available

    Clin Cancer Res

  41. MAGBANUA MJM, Ahmed Z, Sayaman RW, Brown Swigart L, et al
    Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
    Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-23-2928.
    PubMed         Abstract available

  42. MARTIN M, Yoder R, Salgado R, Del Monte-Millan M, et al
    Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy.
    Clin Cancer Res. 2024 Mar 11. doi: 10.1158/1078-0432.CCR-24-0106.
    PubMed         Abstract available

    Clin Exp Metastasis

  43. LIBRING S, Berestesky ED, Reinhart-King CA
    The movement of mitochondria in breast cancer: internal motility and intercellular transfer of mitochondria.
    Clin Exp Metastasis. 2024 Mar 15. doi: 10.1007/s10585-024-10269.
    PubMed         Abstract available


  44. SHULDINER J, Sutradhar R, Lau C, Shah N, et al
    Longitudinal adherence to surveillance for late effects of cancer treatment: a population-based study of adult survivors of childhood cancer.
    CMAJ. 2024;196:E282-E294.
    PubMed         Abstract available

    Eur J Cancer

  45. UNTCH M, Perol D, Mayer EL, Cortes J, et al
    Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
    Eur J Cancer. 2024;202:113977.
    PubMed         Abstract available

  46. COLOMBO I, Koster KL, Holer L, Haefliger S, et al
    TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
    Eur J Cancer. 2024;201:113588.
    PubMed         Abstract available

  47. BARTELS SAL, van Olmen JP, Scholten AN, Bekers EM, et al
    Real-world data on malignant and borderline phyllodes tumors of the breast: A population-based study of all 921 cases in the Netherlands (1989 -2020).
    Eur J Cancer. 2024;201:113924.
    PubMed         Abstract available

    Eur J Surg Oncol

  48. LOVELAND-JONES C, Gaughan J, Caudle A, Murphy B, et al
    Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry.
    Eur J Surg Oncol. 2024;50:108245.
    PubMed         Abstract available

    Eur Radiol

  49. CAMPS-HERRERO J, Pijnappel R, Balleyguier C
    MR-contrast enhanced mammography (CEM) for follow-up of breast cancer patients: a "pros and cons" debate.
    Eur Radiol. 2024 Mar 15. doi: 10.1007/s00330-024-10684.
    PubMed         Abstract available


  50. QI Q, Zhu M, Li P, Mi Q, et al
    Systematic analysis of PANoptosis-related genes identifies XIAP as a functional oncogene in breast cancer.
    Gene. 2024 Mar 9:148355. doi: 10.1016/j.gene.2024.148355.
    PubMed         Abstract available


  51. AZAM AS, Tsang YW, Thirlwall J, Kimani PK, et al
    Digital pathology for reporting histopathology samples, including cancer screening samples - definitive evidence from a multisite study.
    Histopathology. 2024;84:847-862.
    PubMed         Abstract available

    Int J Cancer

  52. HAN X, Liu Y, Zhang S, Li L, et al
    Improving the diagnosis of ductal carcinoma in situ with microinvasion without immunohistochemistry: An innovative method with H&E-stained and multiphoton microscopy images.
    Int J Cancer. 2024;154:1802-1813.
    PubMed         Abstract available

  53. KREGTING LM, Vrancken Peeters NJMC, Clarijs ME, Koppert LB, et al
    Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness.
    Int J Cancer. 2024 Mar 13. doi: 10.1002/ijc.34899.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  54. BEHZADI ST, Moser R, Kiesl S, Nano J, et al
    Tumor Contact with Internal Mammary Perforator Vessels as Risk Factor for Gross Internal Mammary Lymph Node Involvement in Breast Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2024 Mar 6:S0360-3016(24)00339.
    PubMed         Abstract available

    J Clin Invest

  55. LUO M, Bao L, Xue Y, Zhu M, et al
    ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2.
    J Clin Invest. 2024;134:e171166.
    PubMed         Abstract available

    J Clin Oncol

    Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers.
    J Clin Oncol. 2024 Mar 13:JCO2302763. doi: 10.1200/JCO.23.02763.

  57. BURSTEIN HJ, DeMichele A, Fallowfield L, Somerfield MR, et al
    Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
    J Clin Oncol. 2024 Mar 13:JCO2400248. doi: 10.1200/JCO.24.00248.
    PubMed         Abstract available

  58. MANN GB, Rose AK, Zdenkowski N
    What About This IDEA: The PROSPECT That Occult Malignant Lesions May Explain Local Recurrences in Very Early Breast Cancer?
    J Clin Oncol. 2024 Mar 15:JCO2302729. doi: 10.1200/JCO.23.02729.

    J Natl Cancer Inst

  59. HUBBARD RA, Su YR, Bowles EJ, Ichikawa L, et al
    Predicting five-year interval second breast cancer risk in women with prior breast cancer.
    J Natl Cancer Inst. 2024 Mar 11:djae063. doi: 10.1093.
    PubMed         Abstract available

  60. ZENG E, He W, Sjolander A, Bergqvist J, et al
    Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis.
    J Natl Cancer Inst. 2024 Mar 12:djae061. doi: 10.1093.
    PubMed         Abstract available


  61. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    PubMed         Abstract available

    Nat Rev Clin Oncol

  62. KONTOS D
    The promise of AI in personalized breast cancer screening: are we there yet?
    Nat Rev Clin Oncol. 2024 Mar 12. doi: 10.1038/s41571-024-00877.

    NPJ Breast Cancer

  63. AMATO O, Giannopoulou N, Ignatiadis M
    Circulating tumor DNA validity and potential uses in metastatic breast cancer.
    NPJ Breast Cancer. 2024;10:21.
    PubMed         Abstract available

  64. LIU H, Zou L, Xu N, Shen H, et al
    Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer.
    NPJ Breast Cancer. 2024;10:22.
    PubMed         Abstract available


  65. ZENGIN HB, Tan PH, Liu R, Smoller BR, et al
    'Eczematous' dermatitis of the nipple: clinical and histopathological differential diagnosis of Paget disease.
    Pathology. 2024;56:300-312.
    PubMed         Abstract available

  66. TAY TKY, Tan GS, Lee SH, Sam XX, et al
    Comparison of an amplicon-based large panel next generation sequencing (NGS) assay with conventional testing methods for MET and HER2 amplification in lung and breast cancers.
    Pathology. 2024;56:325-333.
    PubMed         Abstract available

    PLoS One

  67. NGUYEN AQ, Tran OTM, Nguyen PK, Nguyen HT, et al
    Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
    PLoS One. 2024;19:e0300474.
    PubMed         Abstract available

  68. NORTHGRAVES M, Cohen J, Harvey J, Huang C, et al
    A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) - Study protocol.
    PLoS One. 2024;19:e0300339.
    PubMed         Abstract available

  69. ZHU JJ, Huang FY, Chen H, Zhang YL, et al
    Autocrine phosphatase PDP2 inhibits ferroptosis by dephosphorylating ACSL4 in the Luminal A Breast Cancer.
    PLoS One. 2024;19:e0299571.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.